Navigation Links
Watson Reaches Settlement with Teva Over Seasonale(R)
Date:5/7/2010

MORRISTOWN, N.J., May 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.

On December 13, 2007, Teva filed a patent infringement lawsuit against Watson in the United States District Court for the District of New Jersey involving Watson's Quasense® product, which is a generic equivalent of Teva's Seasonale®.  Under terms of the settlement agreement, Teva has granted Watson a fully paid-up license to the U.S. patents covering Seasonale® and Watson will continue marketing its generic equivalent product Quasense® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg).  Watson further admits that the licensed patents are valid and enforceable.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Confirms EVISTA(R) Patent Challenge
2. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th
3. Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference
4. Watson Confirms Trilipix(R) Patent Challenge
5. Watson Confirms Rapamune(R) Patent Challenge
6. Watson Confirms Cenestin(R) Patent Challenge
7. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
8. Watson to Present at Barclays 2010 Global Healthcare Conference
9. Watson Receives FDA Approval for Generic Cardizem(R) LA
10. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
11. Watson Announces Actos(R) Patent Challenge Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, today announced ... trial of  VAL-083  (dianhydrogalactitol) in patients with refractory ... form of human brain cancer. Results ...
(Date:6/1/2015)... CEFALY Technology , the creators of ... authorized for use prior to the onset of migraine ... trial showing that the Cefaly device returns normal metabolic ... patients, namely the orbitofrontal cortex and rostral cingulate. ... an imaging test of the brain, used a radioactive substance called a ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... Clinical Development for the Treatment of ... Opioid Bowel Dysfunction, ... presented positive results this week from Phase,1 and preclinical studies of ... in Las Vegas, Nevada. NKTR-118 is,Nektar,s proprietary oral therapy being studied ...
... physician leading clinical trials, FREEPORT, N.Y., ... in treating facial bruising from injectable cosmetic,treatments ... known for,treating under-eye circles. Pinoxide is ... (BMTd),created by AGI Dermatics and formulated in ...
Cached Medicine Technology:Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 2Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 3Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 4Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 5Promising Results in Treating Facial Bruising From Injectables 2
(Date:6/1/2015)... 2015 On May 14, 2015, the ... hosted the Cherry Creek Chamber of Commerce for the ... care centers typically do not offer primary care services ... Cherry Creek Urgent Care staff to schedule family care ... 5:30 to 7:30 p.m. the center hosted presidents, CEOs, ...
(Date:6/1/2015)... Portland, Ore. (PRWEB) June 01, 2015 ... Plans (AHIP) announced today a new, interactive Affordable ... support large employers. The course, called “Affordable Care ... care professionals with the strategic and consultative insights ... employers as they navigate the impacts of the ...
(Date:6/1/2015)... June 01, 2015 Note: Dr. Julian ... in breast cancer prevention. , A phase III trial ... postmenopausal women with ductal carcinoma in situ (DCIS) now ... prevention. , The study (NSABP B-35/NRG Oncology) looked at ... the standard five-year treatment with tamoxifen to those who ...
(Date:6/1/2015)... June 01, 2015 More than 22 million ... months when school is out and they lose access to ... and America’s dairy farmers and milk companies are on a ... with The Great American Milk Drive. , In many ... in the school cafeteria for the bulk of their daily ...
(Date:6/1/2015)... 2015 June 1, 2015 – Atlanta, ... in the areas of hospital medicine, emergency medicine, and ... has expanded upon its partnership with AgileMD to provide ... Practice, in a mobile application format available on ... “We are very excited about the June 1 launch ...
Breaking Medicine News(10 mins):Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3
... , ... Data Advantage, LLC recently named two QHR ... list. Fort Madison Community Hospital (Fort Madison, Iowa), a QHR management ... management client since 1979, were lauded by the company, which specializes ...
... Dec. 20 (HealthDay News) -- Think twice before you put that ... You may get it and find out you don,t really need ... a new study suggests. , That,s because "sometimes the reality of ... cappuccino machine is a hassle to clean, the fancy navigation system ...
... ... Province of Quebec following an inquiry that suggested that there might have been testing ... ... served as the reference laboratory for a highly anticipated retesting of nearly 3,000 breast ...
... , WASHINGTON, Dec. 20 ... Bureau: , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) , SUNDAY, DECEMBER ... Sunday, December 20th. The first successful organ transplant in the U.S. ... Joseph Murray. He transplanted a kidney from one identical twin ...
... , , Federal government must not ... not go forward unless and until problems remedied , ... affordability top issues , WASHINGTON, Dec. 19 The ... current form, Cardinal Daniel DiNardo of Galveston-Houston, Bishop William Murphy ...
... electronic health records, concerns about potential privacy breaches remain an ... 2010 issue of the Journal of the American Informatics ... one of 30 specialty titles published by the BMJ ... published study is based on views of more than 1,000 ...
Cached Medicine News:Health News:QHR Hospital Clients Fort Madison Community Hospital, Monroe County Hospital Named to “Best in Value” Top 100 List 2Health News:Be Careful What You Wish For This Holiday Season 2Health News:Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry 2Health News:Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry 3Health News:U.S. Census Bureau Daily Feature for Dec. 20 2Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 2Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 3Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 4Health News:Journal of the American Medical Informatics Association 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: